LITS

#4418
Lite Strategy, Inc. - Common Stock
0.9 8 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.98
0.98
Jahresspanne
0.69
3.23
Tagesänderung
-2.00%
Monatliche Änderung
+3.16%
6 month change
-9.26%
Jahresänderung
-67.11%
Vorheriger Schlusskurs
1.0 0
Open
0.9 8
Tief
0.9 8
Hoch
0.9 8
Volumen
2
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 07 December 2015

Full document

Business Context and Reporting Period

This Form 8-K was filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on December 8, 2015, reporting events occurring on December 7, 2015. The company is a Delaware corporation focused on developing investigational drug candidates, specifically Pracinostat, for the treatment of hematologic malignancies.

Key Financial Metrics

This filing is a Current Report on Form 8-K regarding clinical trial results and strategic announcements. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.

Material Changes and Clinical Updates

  • AML Study Results: The company presented final results from an open-label Phase II clinical study of Pracinostat in combination with azacitidine for elderly patients with newly diagnosed acute myeloid leukemia (AML) at the 57th American Society of Hematology (ASH) Annual Meeting.
  • MDS Study Results: The company presented results from a randomized, double-blind, Phase II clinical study of Pracinostat in combination with azacitidine for patients with previously untreated myelodysplastic syndrome (MDS) at the ASH Conference.
  • Strategic Announcement: Based on the AML study results, the company announced its intent to initiate a Phase III registration study of Pracinostat and azacitidine in elderly patients with newly diagnosed AML in the second half of 2016.

Guidance, Outlook, and Risks

Outlook: Management intends to proceed to Phase III registration for the AML indication in the second half of 2016, contingent on the positive data presented.

Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical development. The progression to Phase III is an intent based on the presented abstracts, which are filed as exhibits.

Investor Verification Checklist

  • Verify the specific efficacy and safety data in the attached abstracts (Exhibits 99.1 and 99.2) to assess the strength of the Phase III justification.
  • Confirm the company's cash runway and funding status to support the planned Phase III trial initiation in 2016, as this filing contains no financial data.
  • Review the full press release (Exhibit 99.3) for any additional details on the study design or statistical significance not captured in the abstract summaries.
  • Monitor regulatory communications regarding the acceptance of the Phase III protocol for the AML indication.